Atrial Fibrillation Trial, Recruiting NCT07122947 Sponsor: The Cleveland Clinic Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT07122947
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 22 years of age or older
  • People who have a documented or current history of atrial fibrillation (an irregular heart rhythm condition), including any type — paroxysmal (comes and goes), persistent, or long-standing persistent
  • People who are scheduled to have planned mitral valve surgery (repair or replacement) that also includes a specific heart rhythm procedure called a Cox-Maze IV ablation, along with a procedure to close off a small pouch in the heart called the left atrial appendage, with or without additional tricuspid valve surgery
  • People who have access to an Apple iPhone
  • People who are willing and able to wear both an Apple Watch and a Zio Patch (a small heart monitoring sticker) at set times throughout the study
  • People who are willing and able to attend follow-up visits and complete surveys over the longer term of the study

Who may not be able to join:

  • People who have a cardiac pacemaker
  • People who have heart failure where the heart's pumping strength is significantly reduced (ejection fraction below 40%)
  • People who are also having aortic valve replacement or coronary artery bypass graft surgery at the same time
  • People with a personal or family history of skin allergies to adhesives or hydrogels (sticky materials used in patches or medical devices)
  • People who have tattoos on the wrist or forearm where the Apple Watch would need to be worn
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marc Gillinov, MD, The Cleveland Clinic

Phone: 216-312-4443

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
2 June 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Accuracy of AF burden

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov